ARO-MAPT / Arrowhead - LARVOL DELTA

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies (Arrowhead Press Release) - "Pending clearance, Arrowhead intends to proceed with a Phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MAPT in up to 64 healthy subjects and up to 48 subjects with early Alzheimer’s disease, defined as mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia."

New P1/2 trial • Alzheimer's Disease • Tauopathies And Synucleinopathies